Skip to main content

Advertisement

Table 2 Adverse events. Adverse events (by NCI-CTCAE v.3 grade) recorded up to 60 days after the start of protocol therapy, from 61 days onwards and across the whole study period (n = 14)

From: Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma

Category/event Day 1 to 60 (n = 14) Day 61 onwards (n = 12) Day 1 to last assessment (n = 14)
  Grade 1–2 Grade ≥3 Grade 1–2 Grade ≥3 Grade 1–2 Grade ≥3
A.       
Gastrointestinal       
 Nausea 10 0 4 1 10 1
 Vomiting 7 0 1 0 8 0
 Anorexia 5 0 5 2 6 2
 Diarrhoea 4 0 1 1 4 1
 Stomatitis 1 0 2 0 2 0
 Mucositis 2 0 0 0 2 0
 Constipation 2 0 1 0 2 0
Pain       
 Abdominal pain 2 0 1 0 3 0
 Pain (non-abdominal) 0 1 0 0 0 1
Constitutional Symptoms       
 Fatigue 6 2 5 5 4 6
 Fever 3 0 0 0 3 0
Hepatobiliary/Pancreas       
 Ascites 0 1 0 3 0 3
 Jaundice 0 0 0 1 0 1
 Liver failure 0 0 0 1 0 1
Neurology       
 Neuropathy 3 0 1 0 3 0
Pulmonary/Upper Respiratory       
 Dyspnoea 1 1 1 1 1 1
 Bruising 1 0 2 0 2 0
 Pneumonia 0 1 1 0 0 1
Vascular       
 Pulmonary embolism 0 1 0 0 0 1
 Deep vein thrombosis 0 1 0 1 0 1
Dermatology/Skin       
 Dry skin/cracked skin 1 1 0 1 1 1
Haemorrhage/Bleeding       
 Epistaxis 1 0 2 0 2 0
Ocular/Visual       
 Epiphora 3 0 3 0 3 0
B.       
Biochemical/Laboratory       
 Hyperbilirubinemia 5 3 2 6 4 7
 Albumin 9 1 8 1 11 1
 Alkaline phosphatase 4 1 8 0 8 1
 Alanine transaminase 8 0 5 0 10 0
 Aspartate aminotransferase 3 0 5 0 6 0
Blood/Bone Marrow       
 Haemoglobin 7 0 3 0 8 0
 Platelets 4 2 5 2 4 4
 Leukocytes 8 1 2 0 8 1
 Neutrophils 2 2 1 1 2 2
  1. A) Any grade 1–2 treatment-related adverse clinical events occurring in >10 % of patients and all grade 3–4 treatment-related adverse clinical events. B) All-cause laboratory events